Physicians' Academy for Cardiovascular Education

RAS blockade in the real world

Slides (presentation) - Oct. 19, 2011

RAS blockade in the real world: From clinical trial data to challenges in daily hypertension management
LIFE: Design and Dosing Titration to target blood pressure: <140 / <90 mmHg
LIFE: Blood Pressure During Follow-up
LIFE: Primary Composite Endpoint
LIFE: Fatal/Non-fatal Stroke
LIFE: ISH – Fatal/Non-fatal Stroke
LIFE Atrial Fibrillation: Losartan vs. Atenolol Reduces New Onset AF/Flutter
SCOPE: Study Design
SCOPE: Baseline Characteristics
SCOPE-ISH: Fatal and Non-fatal Strokes
VALUE: Design Elective Titration to Target BP (<140/90 mmHg)
VALUE: Systolic Blood Pressure in Study
VALUE: Primary Composite Cardiac Endpoint
Reduced Incidence of New Onset Atrial Fibrillation With ARB: the VALUE Trial
VALUE: New-onset Diabetes Valsartan vs Amlodipine
CASE-J: Dosage Schedule (n=4728) (Candesartan Antihypertensive Survival Evaluation in Japan)
Blood Pressure Changes
Primary Composite Endpoints Comparison of Cardiovascular Events
CASE-J: New-onset Diabetes
Binding Ability to the AT1 Receptor
The Real Life Study: Hypothesis and Aim
Study Cites in Uppsala Area, Sweden
Health Care in Sweden
Extraction Method
Data Extraction in Primary Care
Prescription Patterns at Study Centers
Included Patients Per Year
Selection Method
Baseline Characteristics
Up-titration of ARB
Ratio (candesartan/losartan)
Follow-up Time (months)
Blood Pressure Reduction
ARB Titration
Concomitant Medication
Limitations
Conclusion – Conduct of Real Life
CVD Risk
Risk of Separate Endpoints
Hazard Ratio
Additional Adjustments
REAL LIFE: Conclusions
Association of Candesartan vs Losartan With All-Cause Mortality in Patients With Heart Failure
Overall Survival
Survival Women
EF >40%
NYHA I
Conclusions Swedish Heart Failure Registry Study
Meta-Analysis Cancer Incidence ARBs
Cancer in 15 ARB Trials : ARB vs. non ARB
Overall Conclusions

Share this page with your colleagues and friends: